Kura Oncology: Engaging Investors at Upcoming Conference

Author: Riley Hayes Updated: 09-24-2025 07:44 AM

Kura Oncology's Upcoming Engagement with Investors

Kura Oncology, Inc. (NASDAQ: KURA) is making strides in the biopharmaceutical sector, focusing on precision medicine to combat cancer. The management team has announced an exciting opportunity for investors as they prepare to participate in a key investor conference.

Event Details of the Investor Conference

Kura will be featured at the UBS Virtual Oncology Day, scheduled for a strategic time slot that maximizes engagement: Wednesday, October 1, 2025, at 2:30 p.m. ET / 11:30 a.m. PT. This event represents a vital platform for Kura to connect with current and potential investors, presenting critical insights into their groundbreaking research and development efforts.

How to Access the Live Webcast

Investors interested in following Kura's presentations can do so through a live audio webcast accessible via the Investors section of Kura's official website. An archived replay will also be made available for those unable to attend live.

Understanding Kura Oncology's Mission

At the heart of Kura Oncology's mission is the commitment to developing cutting-edge therapies that hold the potential to change the way cancer is treated. As a clinical-stage biopharmaceutical company, Kura focuses on formulating small molecule drug candidates, specifically designed to target cancer signaling pathways. This approach aims to address high-need hematologic malignancies and solid tumors effectively.

Innovative Therapies in Development

Kura's pipeline includes ziftomenib, a menin inhibitor that targets specific genetic mutations seen in acute myeloid leukemia. By innovating within the realms of menin inhibition and farnesyl transferase inhibition, Kura Oncology is dedicated to overcoming the challenges posed by adaptive and innate resistance encountered when treating solid tumors.

The Importance of Investor Communication

Engaging with investors is not merely a formality; it is fundamental to Kura's progress as an organization. By providing updates on their pipeline and research initiatives, Kura emphasizes transparency and builds trust with stakeholders who are investing in the future of cancer therapy.

Continued Growth Through Investor Interaction

Investor conferences open doors to essential discussions about advancements in medical science, financial prospects, and community alignment. Kura Oncology recognizes the significance of these interactions, ensuring continuous growth and improvement through investor feedback and engagement.

Company Contacts for Further Information

For those who wish to learn more about Kura Oncology, the company encourages inquiries from investors and media alike. Greg Mann, who handles investor and media relations can be reached at 858-987-4046 or via email.

Frequently Asked Questions

1. What is the main focus of Kura Oncology?

Kura Oncology is primarily dedicated to developing precision medicines for cancer treatment.

2. Where can I find information about the investor conference?

Details about the conference can be found on Kura's official website under the Investors section.

3. What is ziftomenib?

Ziftomenib is a drug candidate being developed by Kura that targets genetic drivers of acute myeloid leukaemias.

4. Why is investor engagement important for Kura?

Investor engagement helps Kura maintain transparency and build trust while gaining insights for growth.

5. Who can I contact for more information about Kura Oncology?

For inquiries, you can contact Greg Mann from Kura's investor relations team.

About The Author

Riley Hayes here, a financial writer and specialist committed to assisting individuals in navigating the intricate world of finance. My love is using my blog and articles to simplify complex financial ideas into understandable, doable guidance. Having worked in finance for many years, I try to give my readers the information and resources they need to make wise financial choices.

Writing for several financial blogs has let me connect with a wide range of readers, from novice investors seeking new ideas to seasoned investors. My mission is to make money interesting and approachable so you may take charge of your financial future. I appreciate you traveling with me toward success and financial literacy.

Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.